Cellect Biotechnology Ltd. (NASDAQ: APOP) Announced Completion of First ApoFraft Bone Marrow Transplant In The US

Cellect Biotechnology Ltd. (NASDAQ: APOP) has announced its first ApoGraft transplantation in its clinical study at Washington University in a patient with Leukemia. 

EnCellX to acquired ApoGraft technology 

The company has produced ApoGraft based on its cell selection tech developed for immune therapy optimization.  Notably, in the application, the ApoGraft is meant to prevent graft-versus-host disease after a bone marrow transplant. 

Privately held US- firm, EnCellX will pursue ApoGraft’s development. The firm is purchasing Cellect’s intellectual technology concurrently with the previously announced strategic merger deal between Quoin Pharmaceuticals and Cellect.  Initially, the study will recruit 18 patients with haploidentical bone marrow transplantation having hematological malignancies (BMT).  Recruitment of patients offers momentum needed to start fundraising for the development of the technology under EnCellX. EnCellX is raising funding from renowned healthcare institutional investors, led by Founder and CEO Adi Mohanty, to accelerate and expand clinical development.

CEO Dr. Shai Yarkoni said, “This is an important milestone for Cellect and demonstrates the team’s professionalism and dedication for getting us to this occasion. We look forward to working closely with EnCellX as its U.S. based team will work closely with Washington University to continue patient enrollment. This achievement, following the release of positive topline data from the Israeli ApoGraftTM trial, is timely as EnCellX is seeking to strengthen its balance sheet in the near term to fund continuing clinical development.”

Cellect’s tech to help in stem cell selection 

Cellect has developed a novel tech that allows stem cell selection from any kind of tissue aimed at enhancing a range of cell-based therapies.  The company’s technology is anticipated to give researchers, clinicians, and pharmaceutical companies the ability to swiftly isolate specific cells in large quantities and of high quality, permitting cell-based procedures and treatments in a wide range of regenerative medicine applications. For example, Cellect is now conducting a clinical trial for bone marrow transplants in cancer treatment.